Intellectual Property Watch

Intellectual Property Watch

  • Articles: 409

US Congress Committee Issues Report On “Highly Invasive” FDA Surveillance Of Employees

The United States House of Representatives Committee on Oversight and Government Reform today released a report detailing the US Food and Drug Administration's "highly-invasive" surveillance programme that monitored employees who contacted Congress and the media, according to a press release from the committee leaders. Surveillance was unauthorised and whistleblowers were not given sufficient protection, the report found.

Infojustice: Graphics Show Rise In US Pharma Exports To India, Patent Grants By India

Mike Palmedo at Infojustice.org writes: "The U.S. International Trade Commission (ITC) is currently investigating “Indian industrial policies that discriminate against U.S. imports… and the effect those barriers have on the U.S. economy and U.S. jobs.” The investigation was requested by Sen. Hatch, Sen. Baucus, Rep. Camp, and Rep. Levin, and the final report is due to be released in November. Last week it held a series of hearings, where it heard from U.S. business, Indian business, and civil society representatives."

Infojustice.org: Australia Commits To Overhaul Of Copyright Act

From infojustice.org: [Australian Digital Alliance] It has been a big week for Australian Copyright. On Thursday the Attorney-General, the Hon George Brandis QC, tabled the long-anticipated final report from the Australian Law Reform Commission’s (ALRC) Copyright and the Digital Economy inquiry. This inquiry was charged with determining if copyright exceptions and limitations were working in the digital age. The conclusion was that reform was needed.

Alert: Pharma IPR 2014 Conference In Mumbai, 26-28 February

Dear Subscribers,

CPhI's 3rd Annual Pharma IPR 2014 conference to take place from 26-28 February, 2014 in Mumbai, India will have techno-legal experts from over 10+ regions speaking on the recent case studies on global Pharma and Biopharma patent laws.

Among them, Jeffery Alan Hovden, Partner, Robins, Kaplan, Miller & Ciresi LLP from US will be speaking on critical developments in US pharma patent law in the year 2013 which have affected pharma and biopharma industry. He will also share best strategies on how Indian generic-drug and biologics enterprises need to go forward with their US-related projects.

Some of the critical concerns he is planning to address include:

  • Which pharmaceutical and diagnostic compounds and processes can even obtain a US patent?
  • Whether the new, cheap and fast patent-challenge procedures are right for Indian companies in the life-sciences area?
  • How to avoid paying the attorney fees for the other side in US litigation and indeed, how an Indian company might turn the tables and have the other side pay the company’s attorney fees?

You can view his insights on "US Patent Law in 2013: Winds of Change" by clicking here.

To optimise interactions with the audience, he and other global techno-legal experts would also be available in query handling sessions as well as one-on-one meetings, to discuss your concerns related to the US patent system. Click here to go through the detailed programme agenda.

You can read more about the conference speakers here.
To be a part of this exclusive event, please contact the organisers at +91 (22) 6172 7001 / conferences-india@ubm.com, or register online and take advantage of the special offers for you as you are our subscribers.

P.S. You may find one of his earlier presentations on “From Small to Big: Some useful points in the coming shift from customary drugs to biologics” interesting - View the presentation here

Global Health 2035 Report: Flawed Projections

Daniele Dionisio writes: Hopes that a comprehensive global health goal could be reached by 2035 are hardly credible with the load of unresolved issues still on the table. This article turns the spotlight on much-debated relevant questions that were left out or under-scrutinised in a recently published Lancet report.

Event: The 6th Annual Corporate IP Counsel Forum

March 19-20, 2014 – Affinia Manhattan – New York City – www.worldcongress.com/corporateIP

Optimize your IP portfolio. In this cross-industry event, the most timely and critical issues will be discussed and analyzed by senior counsel from Bank of America, General Mills, Honeywell, IBM, MLB Advanced Media, MasterCard, S.C. Johnson, and more; providing insight and strategies to help you tackle the latest challenges in IP.

IP-Watch Reader Discount: when reserving your seat, use promo code IPW200 to take $200.00 off the current registration fee.

Global Pharma, Biopharma Patent Laws In Spotlight At CPhI’s Pharma IPR Conference in India

An upcoming conference in Mumbai, India will look at patent laws related to the pharmaceutical and biopharma industries regionally and internationally.

CPhI's 3rd Annual Pharma IPR 2014, taking place from 26-28 February, is a targeted conference focusing on patent related matters for pharma and biopharma industry across the globe. It is intended to provide an ideal learning and networking platform where techno-legal experts from patent law firms across the globe share an update on patent regimes, changes in patent laws, and enforceability of patent laws in different regions with the pharma and biopharma companies.

The conference agenda will cover most debated subjects like: inter-partes review; one year after the implementation of the America Invents Act; reverse payments settlements cases; current implementation of the Unitary Patent System in the EU; and formulating strategies to introduce generic products in international markets.

The programme will cover patent laws of over 13 regions including the US, EU, Japan, Mexico, Canada, India, South East Asia, and Gulf Corporation Council (GCC) countries.

Click here to view the region-wise agenda.

Free download for IP-Watch Readers! Click here to view presentations from 2013!